ArticleJournal of Korean medical science2019
Recurrence Rate of Herpes Zoster and Its Risk Factors: a Population-based Cohort Study.
Article in Journal of Korean medical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05952271 (Nationwide Retrospective Observational Study of Herpes Zoster Associated Hospital Admissions in Italy), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nationwide Retrospective Observational Study of Herpes Zoster Associated Hospital Admissions in Italy
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Clinical Characteristics and Prognostic Factors Associated with Herpes Zoster in Patients with Malignant Tumors: A Systematic Review and Meta-analysis.Anti-cancer agents in medicinal chemistry · 2026Pooled it
- A systematic review and meta-analysis of herpes zoster risk in adults with immunocompromised conditions and autoimmune diseases in Asia-Pacific.Human vaccines & immunotherapeutics · 2025Pooled it
- A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.Human vaccines & immunotherapeutics · 2024Pooled it
- Safety, tolerability of ES16001, a novel varicella zoster virus reactivation inhibitor, in healthy adults.European journal of medical research · 2021Trial
- Bridging the intention‒behavior gap in herpes zoster vaccination: A nationwide survey in a self-payment setting.Human vaccines & immunotherapeutics · 2026Article
- Burden of herpes zoster and postherpetic neuralgia in Jinan, China: incidence, recurrence, and direct medical costs, 2018-2023, a population-based retrospective cohort study.BMC infectious diseases · 2026Article
- Epidemiological Trends of Herpes Zoster in Korea, 2010-2022: A Nationwide Study Using National Health Insurance Data.Journal of Korean medical science · 2026Article
- Cost-utility and budget impact analysis of herpes zoster vaccines in Thai patients with end-stage renal disease.Journal of pharmaceutical policy and practice · 2026Article
- Health and economic burden of herpes zoster in adults in Finland: A retrospective nationwide database study.Human vaccines & immunotherapeutics · 2025Article
- Herpes Zoster: Risk Factors for Occurrence, Complications, and Recurrence with a Focus on Immunocompromised Patients.Diseases (Basel, Switzerland) · 2025Review
- Strategic latency with temporal mutualism: a coevolutionary model of the host-varicella-zoster virus relationship.Frontiers in immunology · 2025Article
- Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.Human vaccines & immunotherapeutics · 2024Article
- Herpes Zoster Recurrence: A Narrative Review of the Literature.Dermatology and therapy · 2024Review
- Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination.Vaccines · 2024Review
- Public health impact of herpes zoster vaccination on older adults in Hong Kong.Human vaccines & immunotherapeutics · 2023Article
- Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study.Infection & chemotherapy · 2023Article
- Burden of Herpes Zoster in Individuals with Immunocompromised Conditions and Autoimmune Diseases in the Republic of Korea: A Nationwide Population-Based Database Study.Infectious diseases and therapy · 2023Article
- Pharmacological Treatment of Herpes Zoster and Factors Associated with Its Recurrence.Antibiotics (Basel, Switzerland) · 2023Article
- Herpes Zoster after COVID-19 Infection or Vaccination: A Prospective Cohort Study in a Tertiary Dermatology Clinic.Dermatology research and practice · 2023Article
- [Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients].Journal francais d'ophtalmologie · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes zoster (HZ) is generally thought to occur once in a lifetime and recurrence is considered to be limited to immunocompromised individuals. Although HZ recurrence rates seem to be increasing, there have been few studies exploring these rates in the general population. We investigated the recurrence rate and associated risk factors in the general population.
methodsWe used the population-based samples of the National Health Insurance Service database to identify cases of initial HZ episodes from January 1, 2002 to December 31, 2013. We also followed up on these cases through December 31, 2013 to identify recurrence.
resultsOverall, the incidence rate of HZ is 5.1 per 1,000 person years and the recurrence rate is 12.0 per 1,000 person years. There were 2,100 recurrent cases out of 39,441 initial episodes with 4.4 years of the mean follow-up period. We identified significant risk factors for recurrence such as old age (51-70 years) (hazard ratio [HR], 1.447; 95% confidence interval [CI], 1.311-1.598), women (1.476; 1.345-1.619), zoster-related pain (ZRP) longer than 30 days (cases of ZRP lasting 31-90 days [1.200; 1.042-1.383], and ZRP lasting longer than 90 days [2.293; 1.990-2.643]). Concurrent hematologic malignancies (2.864; 1.929-4.251), autoimmune diseases (1.466; 1.252-1.715), dyslipidemia (1.390; 1.263-1.530), and hypertension (1.222; 1.107-1.350) were also significant risk factors.
conclusionOur results suggest that the recurrence of HZ is much more common than generally expected, and that the associated risk factors can play an important role in predicting recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.